Compare Stocks: INMB, FHTX, IVVD, and RNAC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FHTX Foghorn Therapeutics	$4.17 +1.2%	$5.52	$3.27 ▼ $7.61	$244.67M	2.86	409,017 shs	354,919 shs
INMB INmune Bio	$2.05 -9.3%	$2.09	$1.09 ▼ $2.60	$62.72M	0.93	314,528 shs	921,565 shs
IVVD Invivyd	$0.81 -3.0%	$0.76	$0.53 ▼ $3.07	$244.65M	0.81	4.05 million shs	3.58 million shs
RNAC Cartesian Therapeutics	$7.91 +0.3%	$8.77	$5.60 ▼ $11.00	$238.71M	0.62	117,090 shs	117,995 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FHTX Foghorn Therapeutics	+1.21%	-10.71%	-38.13%	+0.48%	-14.90%
INMB INmune Bio	-9.29%	-16.67%	-3.76%	+41.38%	+3.02%
IVVD Invivyd	-2.98%	+1.00%	+8.75%	-16.97%	-36.09%
RNAC Cartesian Therapeutics	+0.25%	-8.98%	-13.83%	-17.86%	-17.60%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FHTX Foghorn Therapeutics	$4.17 +1.2%	$5.52	$3.27 ▼ $7.61	$244.67M	2.86	409,017 shs	354,919 shs
INMB INmune Bio	$2.05 -9.3%	$2.09	$1.09 ▼ $2.60	$62.72M	0.93	314,528 shs	921,565 shs
IVVD Invivyd	$0.81 -3.0%	$0.76	$0.53 ▼ $3.07	$244.65M	0.81	4.05 million shs	3.58 million shs
RNAC Cartesian Therapeutics	$7.91 +0.3%	$8.77	$5.60 ▼ $11.00	$238.71M	0.62	117,090 shs	117,995 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FHTX Foghorn Therapeutics	+1.21%	-10.71%	-38.13%	+0.48%	-14.90%
INMB INmune Bio	-9.29%	-16.67%	-3.76%	+41.38%	+3.02%
IVVD Invivyd	-2.98%	+1.00%	+8.75%	-16.97%	-36.09%
RNAC Cartesian Therapeutics	+0.25%	-8.98%	-13.83%	-17.86%	-17.60%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FHTX Foghorn Therapeutics	2.71	Moderate Buy	$11.67	179.78% Upside
INMB INmune Bio	2.50	Moderate Buy	N/A	N/A
IVVD Invivyd	2.33	Hold	$8.00	893.42% Upside
RNAC Cartesian Therapeutics	2.57	Moderate Buy	$32.60	312.14% Upside

Current Analyst Ratings Breakdown

Latest INMB, FHTX, IVVD, and RNAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	IVVD Invivyd	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/9/2026	RNAC Cartesian Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/8/2026	IVVD Invivyd	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	IVVD Invivyd	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/24/2026	IVVD Invivyd	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/19/2026	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/18/2026	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/18/2026	RNAC Cartesian Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$38.00
8/5/2026	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/29/2026	RNAC Cartesian Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/24/2026	IVVD Invivyd	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FHTX Foghorn Therapeutics	$30.91M	8.01	N/A	N/A	($1.92) per share	-2.17
INMB INmune Bio	$50K	1,137.75	N/A	N/A	$0.88 per share	2.33
IVVD Invivyd	$53.43M	4.44	N/A	N/A	$1.04 per share	0.77
RNAC Cartesian Therapeutics	$2.80M	85.46	N/A	N/A	($4.85) per share	-1.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FHTX Foghorn Therapeutics	-$74.28M	-$0.98	N/A	N/A	N/A	-175.78%	N/A	-31.17%	11/4/2026 (Estimated)
INMB INmune Bio	-$45.93M	-$0.67	N/A	N/A	N/A	N/A	-82.87%	-62.23%	10/29/2026 (Estimated)
IVVD Invivyd	-$52.49M	-$0.33	N/A	N/A	N/A	-183.90%	-59.73%	-48.97%	11/5/2026 (Estimated)
RNAC Cartesian Therapeutics	-$130.30M	-$5.94	N/A	N/A	N/A	-8,550.65%	N/A	-29.84%	11/5/2026 (Estimated)

Latest INMB, FHTX, IVVD, and RNAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	IVVD Invivyd	-$0.1067	-$0.14	-$0.0333	-$0.14	$14.40 million	$14.29 million
8/6/2026	Q2 2026	FHTX Foghorn Therapeutics	-$0.2450	-$0.10	+$0.1450	-$0.10	$6.81 million	$16.10 million
8/6/2026	Q2 2026	INMB INmune Bio	-$0.2067	-$0.05	+$0.1567	-$0.05	$1.16 million	N/A
8/6/2026	Q2 2026	RNAC Cartesian Therapeutics	-$0.8779	$0.46	+$1.3379	$0.46	$0.18 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
IVVD Invivyd	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FHTX Foghorn Therapeutics	N/A	3.36	3.36
INMB INmune Bio	N/A	4.04	4.04
IVVD Invivyd	N/A	5.87	5.87
RNAC Cartesian Therapeutics	N/A	7.48	7.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FHTX Foghorn Therapeutics	61.55%
INMB INmune Bio	12.72%
IVVD Invivyd	70.36%
RNAC Cartesian Therapeutics	86.95%

Insider Ownership

Company	Insider Ownership
FHTX Foghorn Therapeutics	9.02%
INMB INmune Bio	21.40%
IVVD Invivyd	12.25%
RNAC Cartesian Therapeutics	37.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FHTX Foghorn Therapeutics	106	59.38 million	54.03 million	Optionable
INMB INmune Bio	21	27.75 million	21.82 million	Optionable
IVVD Invivyd	122	294.76 million	258.65 million	Optionable
RNAC Cartesian Therapeutics	75	30.25 million	19.00 million	Optionable

INMB, FHTX, IVVD, and RNAC Headlines

Recent News About These Companies

Cartesian Therapeutics Announces New Employment Inducement Grants

September 8, 2026 | globenewswire.com

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

September 3, 2026 | globenewswire.com

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Recommendation of "Moderate Buy" by Brokerages

August 24, 2026 | marketbeat.com

Wedbush Reiterates Outperform Rating for Cartesian Therapeutics (NASDAQ:RNAC)

August 18, 2026 | marketbeat.com

Cantor Fitzgerald Keeps Their Buy Rating on Cartesian Therapeutics (RNAC)

August 9, 2026 | theglobeandmail.com

Cartesian Therapeutics Announces New Employment Inducement Grants

August 7, 2026 | globenewswire.com

Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 6, 2026 | markets.businessinsider.com

Cartesian Therapeutics Reports Q2 2026 Results, Advances Descartes-08 Clinical Trials and WestGene In Vivo Partnership

August 6, 2026 | quiverquant.comQ

Cartesian Therapeutics Inc RNAC

July 12, 2026 | morningstar.comM

Cartesian Therapeutics (RNAC) Receives a Rating Update from a Top Analyst

July 2, 2026 | theglobeandmail.com

Cartesian Therapeutics Announces New Employment Inducement Grants

July 2, 2026 | globenewswire.com

New Strong Sell Stocks for July 1st

July 1, 2026 | zacks.com

Cartesian Therapeutics Shareholders Back Directors and Governance Measures

June 17, 2026 | tipranks.com

Cartesian Therapeutics Announces New Employment Inducement Grant

June 12, 2026 | globenewswire.com

Wedbush Sticks to Their Buy Rating for Cartesian Therapeutics (RNAC)

June 12, 2026 | theglobeandmail.com

Cartesian climbs on licensing deal with WestGene for CAR-T therapies

June 9, 2026 | seekingalpha.com

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

June 9, 2026 | globenewswire.com

Cartesian Therapeutics (RNAC) Gets a Buy from Wedbush

May 29, 2026 | theglobeandmail.com

Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027

May 26, 2026 | globenewswire.com

We're Keeping An Eye On Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Rate

May 17, 2026 | finance.yahoo.com

Cartesian Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference

May 12, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

INMB, FHTX, IVVD, and RNAC Company Descriptions

Foghorn Therapeutics NASDAQ:FHTX

$4.17 +0.05 (+1.21%)

Closing price 09/16/2026 04:00 PM Eastern

Extended Trading

$4.22 +0.05 (+1.18%)

As of 09/16/2026 07:38 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

INmune Bio NASDAQ:INMB

$2.05 -0.21 (-9.29%)

Closing price 09/16/2026 04:00 PM Eastern

Extended Trading

$2.02 -0.03 (-1.32%)

As of 09/16/2026 07:50 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Invivyd NASDAQ:IVVD

$0.81 -0.02 (-2.98%)

Closing price 09/16/2026 04:00 PM Eastern

Extended Trading

$0.82 +0.01 (+1.83%)

As of 09/16/2026 07:44 PM Eastern

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Cartesian Therapeutics NASDAQ:RNAC

$7.91 +0.02 (+0.25%)

Closing price 09/16/2026 04:00 PM Eastern

Extended Trading

$7.90 -0.01 (-0.13%)

As of 09/16/2026 07:30 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INMB, FHTX, IVVD, and RNAC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INMB, FHTX, IVVD, and RNAC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INMB, FHTX, IVVD, and RNAC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INMB, FHTX, IVVD, and RNAC Company Descriptions

Foghorn Therapeutics NASDAQ:FHTX

INmune Bio NASDAQ:INMB

Invivyd NASDAQ:IVVD

Cartesian Therapeutics NASDAQ:RNAC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INMB, FHTX, IVVD, and RNAC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INMB, FHTX, IVVD, and RNAC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INMB, FHTX, IVVD, and RNAC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INMB, FHTX, IVVD, and RNAC Company Descriptions

Foghorn Therapeutics NASDAQ:FHTX

INmune Bio NASDAQ:INMB

Invivyd NASDAQ:IVVD

Cartesian Therapeutics NASDAQ:RNAC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools